Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 150 of 198 entries
View as:

Study of SHR-A1811 in HER2-expression Advanced Breast Cancer with Brain Metastases

Phase: N/A Priority: Normal
NCT ID: NCT05769010 Org: User:
Start: 03/31/23 End: 04/30/26 Due: 04/30/27

Rituximab,Zanubrutinib in Combination With Lenalidomide, Followed by Zanubrutinib or Lenalidomide Maintenance in Patients With Primary or Secondary CNS Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT04938297 Org: User:
Start: 05/26/21 End: 12/31/25 Due: 12/31/26

GM1 in the Treatment of Neurotoxicity Induced by Albumin-bound Paclitaxel

Phase: N/A Priority: Normal
NCT ID: NCT04538833 Org: User:
Start: 09/09/20 End: 08/22/22 Due: 08/22/23

Patient-derived Organoid Drug Sensitivity Guided Treatment for Drug-resistant Recurrent Non-Small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06406608 Org: User:
Start: 04/16/24 End: 06/16/26 Due: 06/16/27

The Efficacy of Oral Cryotherapy in Preventing TROP2-ADC-Induced Oral Mucositis in Patients With Advanced Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06934733 Org: User:
Start: 05/31/25 End: 05/31/27 Due: 05/31/28

Adjuvant Sintilimab for Locally Advanced Esophageal Squamous Cell Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT05495152 Org: User:
Start: 08/01/22 End: 08/31/28 Due: 08/31/29

QL1706 for the Neoadjuvant Treatment of HR+/HER2- Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06967103 Org: User:
Start: 05/20/25 End: 05/30/29 Due: 05/30/30

Carrilizumab Combined With White Purple for Squamous Cell Carcinoma of Skin

Phase: N/A Priority: Normal
NCT ID: NCT05886140 Org: User:
Start: 06/08/23 End: 04/30/25 Due: 04/30/26

Organoid-guided Personalized Treatment of Pleural Effusion

Phase: N/A Priority: Normal
NCT ID: NCT06959173 Org: User:
Start: 02/21/25 End: 01/31/27 Due: 01/31/28

Multicenter, Prospective, Real World Study of Camrelizumab in Cross-line Treatment of Non-small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05547737 Org: User:
Start: 09/21/22 End: 09/21/25 Due: 09/21/26

Study of CT and MR in the Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT04034667 Org: User:
Start: 09/01/19 End: 12/01/23 Due: 12/01/24

Study to Evaluate the Efficacy and Safety of SHR6390 Combined With Pyrotinib in HER2+ Advanced Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT04293276 Org: User:
Start: 04/01/20 End: 05/31/23 Due: 05/31/24

the Efficacy and Safety of 5-HT3 Receptor Antagonist, Dexamethasone or Megestrol Acetate Dispersible Tablets in the Control of Nausea and Vomiting Induced by Highly Emetogenic Chemotherapy

Phase: N/A Priority: Normal
NCT ID: NCT04430361 Org: User:
Start: 09/07/18 End: 05/30/21 Due: 05/30/22

A Multicenter, Real-world Study of Adebrelimab in the Treatment of Extensive Stage Small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06267170 Org: User:
Start: 02/25/24 End: 02/25/26 Due: 02/25/27

Sequential T and I With H101 Via HAI for BCLC C Stage HCC: A Prospective Single-Center Single-Arm Pilot Study

Phase: N/A Priority: Normal
NCT ID: NCT06685354 Org: User:
Start: 11/30/24 End: 10/31/26 Due: 10/31/27

Local Injection and Systemic Therapy in the Treatment of NSCLC.

Phase: N/A Priority: Normal
NCT ID: NCT06618391 Org: User:
Start: 10/08/24 End: 10/30/26 Due: 10/30/27

Combination Followed by Maintenance Chemotherapy Versus CDK4/6 Inhibitor Combined With Endocrine Therapy for HR Low/HER2-negative Advanced Breast Cancer: a Prospective, Randomized, Open-label Phase Ⅱ Clinical Trial

Phase: N/A Priority: Normal
NCT ID: NCT06176534 Org: User:
Start: 01/01/24 End: 12/20/26 Due: 12/20/27

The FLOT Regimen Conversion Therapy of Adenocarcinoma of the Stomach / Gastroesophageal

Phase: N/A Priority: Normal
NCT ID: NCT03451942 Org: User:
Start: 02/05/18 End: 03/31/21 Due: 03/31/22

PD-1 Monoclonal Antibody Combined With FLOT Regimen for Neoadjuvant Therapy of Gastric Adenocarcinoma

Phase: N/A Priority: Normal
NCT ID: NCT04341857 Org: User:
Start: 07/30/19 End: 07/30/22 Due: 07/30/23

Study of Apatinib Plus Etoposide Capsule as the Therapy of Advanced Small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03389087 Org: User:
Start: 11/29/17 End: 11/01/21 Due: 11/01/22

Anlotinib Combined With Pemetrexed And Carboplatin as First-line Treatment in Advanced Nonsquamous NSCLC

Phase: N/A Priority: Normal
NCT ID: NCT03790228 Org: User:
Start: 03/22/19 End: 08/31/21 Due: 08/31/22

Apatinib With Albumin-bound Paclitaxel in Patients With Platinum-resistant Recurrent Ovarian Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03942068 Org: User:
Start: 09/01/19 End: 12/30/20 Due: 12/30/21

A Clinical Study of Hetrombopag Olamine Tablets for Thrombocytopenia Induced by Chemotherapy in Advanced Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05394285 Org: User:
Start: 08/19/22 End: 12/28/24 Due: 12/28/25

Compare the Efficacy of Surgery Combined With Systemic Therapy and Pure Systemic Therapy in Breast Cancer Patients

Phase: N/A Priority: Normal
NCT ID: NCT04199520 Org: User:
Start: 04/15/20 End: 05/01/22 Due: 05/01/23

Adebrelimab and Concurrent Radiochemotherapy as First-line Treatment for Extensive-stage Small-cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06236997 Org: User:
Start: 02/10/24 End: 12/31/27 Due: 12/31/28